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Background. We aimed to explore (i) the short-term retention of intramedullary implanted mesenchymal stem cells BMSCs and
(ii) their impact on the bone blood ﬂow and metabolism in a rat model of hindlimb irradiation. Methods. Three months after 30
Gy irradiation, fourteen animals were referred into 2 groups: a sham-operated group (n = 6) and a treated group (n = 8) in which
111In-labelled BMSCs (2 × 106 cells) were injected in irradiated tibias. Bone blood ﬂow and metabolism were assessed by serial
99mTc-HDP scintigraphy and 1-wk cell retention by recordings of 99mTc/111In activities. Results. The amount of intramedullary
implanted BMSCs was of 70% at 2H, 40% at 48H, and 38% at 168H. Bone blood ﬂow and bone metabolism were signiﬁcantly
increased during the ﬁrst week after cell transplantation, but these eﬀects were found to reduce at 2-mo followup. Conclusion.
Short-term cell retention produced concomitant enhancement in irradiated bone blood ﬂow and metabolism.
1.Introduction
Radiotherapy has been proven to successfully treat local and
regional neoplasic lesions but it may adversely impact on
normal tissues [1]. High vulnerability to irradiation was
alreadydocumentedinvariousbonetissues(pelvis,sternum,
vertebra, clavicle, femoral head, and mandible) [2]w i t h
subsequent deleterious eﬀect on the bone metabolism and
healing leading thereafter to infection, atrophy, pathological
fractures,andosteoradionecrosis.Forinstance,theincidence
of osteoradionecrosis after conventional radiotherapy ranges
from 0.9% to 35% [3], with an increased risk when doses
given to the mandible exceed 60Gy [4]. Thus, irradiation of
the mandible represents the most devastating radiotherapy-
induced complication and might sometimes lead to surgical
resection [5].
Since vascular ischemia is one of predictors of postir-
radiation degeneration, the inception of angiogenesis by
implantation of bone marrow mesenchymal stem cells
(BMSCs) might represent a therapeutic approach for rehabi-
litating the irradiated bone tissue. Such potentiality was
already documented in diverse ischemic pathologies such2 Journal of Biomedicine and Biotechnology
as hindlimb ischemia [6] or myocardial infarction [7, 8].
Previous data regarding the role of BMSCs in the bone
reconstruction have outlined their active contribution in
the bone formation when seeded on various scaﬀolds [9,
10]. In a dog model of mandible segmental defect, the
feasibility of bone reconstruction using morphologic and 3-
Dbeta-tricalciumphosphatescaﬀoldseededwithautologous
BMSCs was highlighted by both bone formation and bone
vascularization [10].
ExperimentswithBMSCsinthetreatmentorthepreven-
tionofradio-induceddamagewerereportedonintestine[11,
12] and skin [13–15] using systemic [14–16]o rl o c a l[ 11, 13]
delivery. Little is known however about the eﬀect of BMSCs
in irradiated bone tissue, and especially, the bioavailability
and biodistribution of these cells within the targeted areas
since their in vivo monitoring is now mandatory to further
understand their beneﬁce.
The study was designed to explore, in a rat model of
hindlimb irradiation, the feasibility of rehabilitating irradi-
ated tibial bone tissue by intramedullary implanted BMSCs.
The assessment of BMSCs’ retention and distribution were
conducted up to 7 days following transplantation using
111In-oxine-labeling technique. Therapeutic eﬀect on bone
perfusionandmetabolismwasdeterminedbyserial 99m-tech-
netium hydroxymethane diphosphonate (99mTc-HDP) pla-
nar scintigraphy.
2.MaterialsandMethods
2.1. Animals. This study was conducted in 14 Wistar rats
(initial body-weight of 410g–460g). All experimental pro-
cedures were in accordance with our local ethical committee
and with the regulations of the Animal Welfare Act of the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals (NIH Publication no. 85-23, Revised
1996).
Three months after experiencing a hindlimb irradiation
with a monodose of 30Gy a 99mTc-HDP scintigraphy was
performed. Thereafter, animals were referred into 2 groups:
a control sham-operated group (n = 6) and a treated group
(n = 8) in which 111In-labelled BMSCs (2 × 106 cells)
were intramedullary injected in irradiated tibial diaphysis;
BMSCs being harvested before irradiation were cultured
until passage 4, and their mesenchymal phenotypes were
evidenced by ﬂow cytometry.
To evaluate changes in bone blood ﬂow and metabolism,
serial 99mTc-HDP planar scintigraphy was scheduled at 3
months after irradiation and at 2 months after the cell
therapy. The early cell retention after the cell therapy
was assessed by additional dual recordings of 99mTc/111in
activities done at 2 hours, 48 hours, and 168 hours after the
cell injection.
2.2. Irradiation Procedures. Irradiation of the hindlimb was
performed under general anesthesia as previously described
[17]. Brieﬂy, the animals were placed in prone position
upon a thick polystyrene phantom and their hindlimb was
immobilized by adhesive tape. The focus skin distance was
70cm, and the ﬁeld size was 20 × 30cm. The collimating
block was positioned on a 0.5cm thick acrylic platform to
shield the body and only irradiated the exposition of the
left hindlimb without the pelvis. Radiation with 60Co was
delivered in a vertical beam from a Theratron 780C X-ray
machinedeliveringgammaraysof1.25MeVenergyanddose
rate of 1.4Gy/min.
2.3. Noninvasive Imaging Procedures
2.3.1. Sequential Planar Scintigraphy. Bone blood ﬂow and
metabolism were assessed using 99mTc-HDP. After the intra-
venous injection of 9 mCi of 99mTc-HDP and under general
anesthesia, the acquisition was recorded using a single-head
gamma camera (Sopha DSX, SMV-GE) equipped with a
1.5mm pinhole collimator (165mm focal length, 44mm
radius of rotation) and with the following parameters:
256 × 256 matrix, 1.14 zoom, and 140 (±20%) keV energy
window. Two acquisitions were performed: a dynamic HDP
uptake (blood ﬂow) consisted of images obtained at 1
second intervals for 60 seconds reﬂecting vascularity and a
delayed (3 hours after) acquisition of HDP uptake reﬂecting
osteoblastic metabolism [18].
Changes in accumulation of the tracer in irradiated
bone and surrounding tissues were evaluated by measuring
uptake within regions of interest (ROI) on the computer-
processedimagessoftware(Dysplay,ConsoleVision,General
Electric). Values were expressed as percentage (%) of total
body activity.
2.3.2. Dual 111In/99mTc Scintigraphy. Planar scintigraphic
images of the body distribution of 111In-labeled BMSCs were
provided by the same single-head gamma camera (Sopha
DSX, SMV-GE) already described [8, 19]. Two 20% energy
windows centered on the 172KeV and 246KeV photopeaks
of 111In were applied. The initial image was recorded 2H
after cell transplantation during a 15-min period and then
at day 2 (48H) and day 7 (168H) during time periods of
20 and 40min, respectively. 111In activity from each image
wasexpressedrelativetothetotalinjectedactivity(totalbody
activity determined at 2H) and after additional corrections
for the physical decay of 111In (2.9 days).
2.3.3. BMSC Isolation, Cell Culture and Flow Cytometry.
Autologous bone marrow cells, harvested from the left tibias
by punction, were cultured and expanded as previous-
ly described in detail elsewhere [19, 20]. Brieﬂy, aspired
whole bone marrow cells were suspended in Iscove’s modi-
ﬁed Dulbecco’s culture medium (Life Technologies, Cergy
Pontoise, France) containing 10% fetal bovine serum (Life
Technologies, Cergy Pontoise, France), 0.1mmol/L β mer-
captoethanol (Sigma, France), 100U/mL penicillin, and
100μg/mL streptomycin. The cells were grown in a 5% hu-
midiﬁed CO2 atmosphere at 37◦C, and the medium was
changed every 2 days.
To ascertainthe mesenchymal phenotype of transplanted
BMSCs, the expression of CD34, CD44, CD45, and CD90
surfaceantigensofcellspriortoimplantation(passage4)wasJournal of Biomedicine and Biotechnology 3
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Figure 1: Animal model of hindlimb irradiation. (a) Examples of pictures showing alopecia of the hindlimb 3 months after irradiation at a
monodose of 30Gy. (b) Examples of scintigraphic imaging showing the decrease of bone 99mTc-HDP on the irradiated hindlimb 3 months
after irradiation.4 Journal of Biomedicine and Biotechnology
0
200
101 102 103 104
CD 44
79.61%
0
200
101 102 103 104
CD 45
1.37%
0
200
101 102 103 104
CD 90
88.37%
0
200
101 102 103 104
0.89%
CD 34
100
100
100
100
(a)
1cm
(b)
Figure 2: Mesenchymal quality of the engrafted BMSCs and injection procedure. (a) ﬂow cytometry data depicting several conventional
surface antigens of mesenchymal cells (CD34−, CD44+, CD45−, and CD90+) prior to implantation (passage 4). (b) technique of
intramedullary injection (left panel) and on the right panel, the arrow indicates the bandage on the surgical site after BMSC engraftment.
Table 1:Pretherapeuticvalueof 99mTc-HDPboneuptakeoftherathindlimbs.Resultswereexpressedaspercentageoftotalcorporelactivity.
Group 1 Group 2
Nonirradiated hindlimb Irradiated hindlimb Nonirradiated hindlimb Irradiated hindlimb
Bone blood ﬂow
Knee 7.9 ±1.08 .3 ±1.28 .1 ±1.38 .3 ±1.3
Tibia 3.82 ±0.63 .0 ±0.8∗ 3.79 ±1.03 .2 ±0.3∗
Foot 2.4 ±0.72 .6 ±0.82 .7 ±0.62 .6 ±0.7
Bone osteoblastic metabolism
Knee 10.3 ±3.09 .9 ±1.71 1 .3 ±4.98 .9 ±1.9
Tibia 2.2 ±0.22 .1 ±0.12 .3 ±0.22 .0 ±0.3
Foot 3.8 ±0.73 .3 ±1.03 .7 ±3.03 .5 ±1.4
∗P<0.05 versus contralateral nonirradiated legs.
analysed using ﬂow cytometry method (FACSCalibur; Bec-
ton Dickinson, Meylan, France) and the Cellquest software
(Becton Dickinson, Meylan, France) [20].
2.4. Intramedullary Implantation of Radiolabeled BMSCs
2.4.1. Cell Labeling and Cell Transplantation. As already des-
cribed [7, 8], BMSCs (2×106 cells/mL) were trypsinised and
incubated at 37◦Cw i t h1 5M B qo f111In-oxine (Mallinckrodt
Medical B.V., Holland) during a 10-min period, the labellingJournal of Biomedicine and Biotechnology 5
Table 2:Post-therapeuticvalueof 99mTc-HDPboneuptakeoftheirradiatedhindlimbs.Resultswereexpressedasrelativetotheunirradiated
hindlimb.
Hindlimb posttherapeutic 48H posttherapeutic 168H posttherapeutic 2 months
Bone blood ﬂow
Knee Irradiated untreated −0.40 ±1.30 −0.76 ±1.62 +0.16 ±0.91
Irradiated treated −0.30 ±0.89 −1.18 ±0.87 +0.20 ±0.98
Tibia Irradiated untreated +0.95 ±1.43 +0.21 ±1.45 −0.01 ± 0.49
Irradiated treated +2.00 ±0.68∗ +0.70 ±1.03∗ +0.40 ±0.53
Foot Irradiated untreated +1.05 ±1.12 +0.26 ±1.57 +0.46 ±0.31
Irradiated treated +1.64 ±1.25 +1.02 ±0.96 +0.56 ±0.90
Bone osteoblastic metabolism
Knee Irradiated untreated −2.12 ±1.25 −1.06 ±1.06 −1.21 ±1.13
Irradiated treated −1.68 ±1.43 −1.57 ±1.44 −1.16 ±0.98
Tibia Irradiated untreated +0.28 ±0.85 −0.04 ±0.67 −0.01 ±0.66
Irradiated treated +0.77 ±0.56∗ +0.47 ±0.58∗ +0.07 ±0.56
Foot Irradiated untreated +0.36 ±0.89 +0.01 ±1.19 +0.07 ±0.59
Irradiated treated +1.07 ±1.21 +0.58 ±0.62 +0.43 ±0.96
∗P<0.05 versus contralateral nonirradiated legs.
process being stopped by 5-min centrifugation at 950g. This
10-min incubation period was previously found to result in
bothasuﬃcientlyhighlabelingeﬃciency(69%)andabsence
of signiﬁcant deterioration of cell viability (96%) [8].
After stab incision, a 1mm diameter drill hole was
performed perpendicularly to the orientation of the tibial
cortical bone. The 111In-labelled cells were conditioned in
a 1mL syringe (2 × 106 cells in 50μL) and were injected
through the mini-invasive perforation into the bone marrow
ofthelefttibia. Topreventleakageoftransplantedcellsinthe
surroundingtissuesabiocompatiblebandage(IRMDentsply
78467 Konstanz Germany) was positioned over the drilling
site.
2.4.2. Statistics. The statistical analysis was carried out with
theStatisticalPackageSPSSversion14.0(SPSS,Inc.,Chicago,
Ill, USA). We used Mann-Whitney tests for the unpaired
comparisons and Wilcoxon tests for the paired comparisons
in each group. For each test, a P value < 0.05 was considered
to be indicative of a signiﬁcant diﬀerence.
3. Results
3.1. Animal Model of Hindlimb Irradiation and Pretherapeutic
Data. No animal died throughout the study’s period. The
30-Gy irradiation induced 3-4 weeks later a persisting
alopecia in the irradiated hindlimb (Figure 1(a)) without
aﬀecting however the daily locomotor activities of those
animals.
At 2-mo scintigraphic imaging, radiation-induced bone
defects appear as areas of attenuation of signal intensity
coveringtheirradiatedlowerlimb,withpronouncedeﬀectin
the tibia (see Figure 1(b), e.g.,). The pretherapeutic data of
the group control and the cell-treated group were resumed
in the Table 1. In both groups, compared with the total
body activity, irradiation of the hindlimb produced similar
alteration in tibial values of bone perfusion blood ﬂow (early
uptake of 99mTc-HDP) and bone osteoblastic metabolism
(late uptake of 99mTc-HDP). For example, bone perfusion
blood ﬂow was 3.2 ± 0.8% at the irradiated tibia compared
to 3.8 ± 1.0% found in the healthy one (P<0.05).
A slight decrease in bone metabolism of circa 10% was
found in irradiated tibias, but values did not reach statistical
signiﬁcance (2.0 ± 0.3% versus 2.3 ± 0.6% found in healthy
counterparts).
3.2. Cell Identiﬁcation, Short-Term In vivoTracking, and Post-
therapeutic Data
3.2.1. Cell Identiﬁcation Prior to the Cell Grafting. Flow
cyto-metry analyses (Figure 2(a)) showed that the engrafted
BMSCsofpassage4expressedstrongexpressionofCD44and
CD90 surface antigens (>80%). Thus, these cells were nega-
tive for CD45 and CD34 (percentage of positive cells were
2.41 ± 2.47% for CD45 and 1.99 ± 2.72% for CD34). These
data were consistent with our previous studies [20] and in
accordance with criteria deﬁned by the International Society
for Cellular Therapy (ISCT) [21].
3.2.2. Eﬀect of BMSCs on Bone Blood Flow and Bone Meta-
bolism in Irradiated Hindlimb. 99mTc-HDP scintigraphic ex-
aminations performed after intramedullary implantation of
BMSCs have documented, especially in the tibial area, a
signiﬁcant rise in both bone blood ﬂow and bone meta-
bolism during the posttherapeutic ﬁrst week (Table 2 and
Figure 5). At 48 hours, the bone blood ﬂow found in
cell-treated tibias was 4.7 ± 0.7% corresponding to an
enhancement of 62% compared to basal pretherapeutic
values (P<0.01). Similarly, the bone metabolism was 35%
higher than that measured before treatment, values were
2.7 ± 0.5% (P<0.01 versus pretherapeutic data). These
eﬀects persisted at 7 days, bone blood ﬂow was 4.5 ± 1.0%
(P<0.01 versus pretherapeutic data), and bone metabolism
was 2.6 ± 0.6% (P<0.05 versus pretherapeutic data). At 2-
mo followup, these uptake values were found to be down to
3.1 ± 1.4% for the bone blood ﬂow and 1.7 ± 0.3% for the
bone metabolism.6 Journal of Biomedicine and Biotechnology
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Figure 3: Example of scintigrams from 111In/99mTc dual-SPECT
showing the short-term retention of 111In-oxine-labeled BMSCs
following intramedullary injection.
4. Discussion
Damage of normal tissue secondary to radiotherapy is still
a major problem in cancer treatment. Stem cell therapy
seems to be a new treatment option in radio-induced tissue
abnormalities [22–24], providing a mean to reduce related
side eﬀects and to improve the quality of life of patients.
In this study, we investigated the feasibility of BMSCs when
injected intramedullary in an experimental rat model of
radio-induced degeneration recently described by our group
[17].
In the present study, 111In-oxine labelling of BMSCs
was successfully used to follow bone retention and body
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Figure 4:In vivo evolutionof 111Inactivityfoundinthetibiaduring
the 7-day followup and estimation of the percentage of BMSCs
retained within the injection site. Calculation of BMSCs retention
in the tibia was deﬁned as the ration of the mean radioactivity in
the tibia to the mean radioactivity that remained in BMSCs at each
time point.
distribution of BMSCS when injected intramedullary within
irradiated bone. 111In-labelled cells have been widely used
in humans in localizing areas of inﬂammation by imaging
the leukocyte distribution [25]. Furthermore, 111In-labelling
techniques have been applied in various experimental set-
tings in animal to analyse the migration of dendritic cells
[26], the biodistribution of transplanted hepatocytes [27],
and of injected MSCs in animals model of heart or lung
disease [7, 28]. As previously described [7], the technique
used here reached a high eﬃciency (69%) with a low toxi-
city (viability > 95%). In addition, it has been previously
demonstrated that the leakage of 111In from labelled cells
resulted in a high 111In uptake in the liver and spleen and
usually had hepatobiliary and renal excretion pathways [7,
29]. This is in accordance with our observations, and no
111In radioactivity was found in bones outside the area of
injection. Approximately 70% of grafted cells could be esti-
mated to be retained within bone damaged area 2 hours after
transplantation. The “disappearance” of radiolabeled graft-
ed cell may be explained by the method used for BMSCs in-
jection which could be associated with a leakage of BMSCs
from the injection site before bandage and residual BMSCs
in the injection syringes. These data are fully consistent with
those of the study of Tran et al. [7], where approximately
60% of 111In labeled BMSCs were still present 2 hours after
directtransplantationinanecroticratmyocardiumandwere
retained within the heart throughout the 7 days of follow-
up. In the present study, after 48 hours, BMSCs number
decreased to approximately 40% and remained un-changed
until the 7th day. The mechanism responsible for cell loss
during the ﬁrst two days remains to be explored. These
results highlighted that at short term, the engrafted BMSCsJournal of Biomedicine and Biotechnology 7
−2
−1.5
−1
−0.5
0
0.5
1
1.5
2
2.5
3 ∗
∗
†
P
r
e
t
h
e
r
a
p
e
u
t
i
c
v
a
l
u
e
P
o
s
t
t
h
e
r
a
p
e
u
t
i
c
v
a
l
u
e
4
8
H
P
o
s
t
t
h
e
r
a
p
e
u
t
i
c
v
a
l
u
e
1
6
8
H
P
o
s
t
t
h
e
r
a
p
e
u
t
i
c
v
a
l
u
e
2
m
o
n
t
h
s
B
o
n
e
b
l
o
o
d
ﬂ
o
w
(
e
a
r
l
y
9
9
m
T
C
-
H
D
P
a
c
t
i
v
i
t
y
r
e
l
a
t
e
d
t
o
u
n
t
r
e
a
t
e
d
h
i
n
d
l
i
m
b
)
(a)
−1
−0.5
0
0.5
1
1.5 ∗
∗
†
P
r
e
t
h
e
r
a
p
e
u
t
i
c
v
a
l
u
e
P
o
s
t
t
h
e
r
a
p
e
u
t
i
c
v
a
l
u
e
4
8
H
P
o
s
t
t
h
e
r
a
p
e
u
t
i
c
v
a
l
u
e
1
6
8
H
P
o
s
t
t
h
e
r
a
p
e
u
t
i
c
v
a
l
u
e
2
m
o
n
t
h
s
B
o
n
e
m
e
t
a
b
o
l
i
s
m
(
l
a
t
e
9
9
m
T
C
-
H
D
P
a
c
t
i
v
i
t
y
r
e
l
a
t
e
d
t
o
u
n
t
r
e
a
t
e
d
h
i
n
d
l
i
m
b
)
(b)
Figure 5: Two-month evolution of bone ﬂood ﬂow (a) and
bone osteoblastic metabolism (b) in irradiated tibias treated with
BMSCs (dark columns) and control (white columns), values being
expressed as relative to baseline (% of uptake variations with regard
to untreated hindlimb values). ∗P<0.05 versus pretherapeutic
data, †P<0.05 versus control group.
remain localized within the area of injection into irradiated
bone.
Many studies of cell therapy using mesenchymal stem
cells [14, 16], used the systemic injection as modality of
administration. In comparison, using local injection, cells
engraftment seems to be better. For example, in Franc ¸ois
et al.’s study [14], rats were transplanted with a dose of
5 × 106 BMSCs 24 hours after irradiation of the hindlimb at
a single dose of 26.5Gy. Fifteen days later, the implantation
rates of BMSCs in bone and bone marrow were, respec-
tively, approximately 12.5% and less than 0.25%. The major
limitation of this approach is constituted by the very low
number of BMSCs that home to the site of injury [30]. A
possible reason for the ineﬃcient engraftment and hom-
ing could be the entrapment of BMSCs in the lungs
[31]. Moreover, vascular ischemia and ﬁbrosis, characteristic
injury of irradiated tissue [1, 32], may prevent homing and
engraftment of BMSCs.
After cell therapy, the bone blood ﬂow and bone
metabolism evolved similarly, and a signiﬁcant increase of
thesevalueswasobservedduringthesevendaysfollowingthe
BMSCs engraftment. The inﬂuence of the surgical procedure
used in the present study would require further investiga-
tion, especially regarding the role of the inﬂammation
cells response and the local recruitment of mesenchymal
stem cells [33] that should have been induced by the
wound healing after drilling the cortical bone. However, the
beneﬁt obtained seems to be transient since 2 months after
cell therapy, blood ﬂow time and bone uptake of 99mTc-
HDP did not diﬀer signiﬁcantly from data measured in
ungrafted animals irradiated at 30Gy. This result slightly
diﬀers from those achieved in our previous study [34], in
which autologous fat was used as source of mesenchymal
stem cell and grafted within irradiated area, inducing clinical
beneﬁt that appeared to be linked to the improvement
of vascular network and disappearance of necrotic area.
Additional results demonstrating the potency of BMSCs
therapy in irradiated tissues were recently reported [35]
describing a case of regenerative reconstruction of a terminal
stage of osteoradionecrosis with BMSCs and progenitor
cells. Another explanation that stands for the short eﬀect
of engrafted BMSCs might be related to the native hypoxic
microenvironment of the medullar area target of the bone.
The BMSCs used here were expanded according to most of
the conventional cell culture procedures, that is, in normoxic
condition (21% O2). Although they have mesenchymal
characteristics, recent works from our group [36] and others
[37] have suggested that BMSC, when cultured under 5%
O2 rather than under 21% O2, had better growth advantage
in long-term cell expansion. Thus, the hypoxic BMSC
expressed more adhesion and extracellular matrix molecules
and displayed more plasticity features. It is then possible that
diﬀerent in vitro conditions during the cell selection and
expansion might lower their ability to repair when reim-
plantedinnativeenvironment.Thishypothesisneedsfurther
experimental evidences.
5. Conclusion
In conclusion, the present study shows the feasibility of the
intramedullary implantation of BMSCs in the attempt to
rehabilitate the irradiated bone. Our data suggested that
BMSCs appear to remain around the injection site, without
evident body redistribution, for at least a 7-day period along
with a transient beneﬁce on bone blood ﬂow and bone
metabolism. Further experiments are required to evaluate
their long-term beneﬁcial eﬀect.
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